Analysts Set Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Price Target at $46.43

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been given a consensus recommendation of “Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $46.4286.

AAPG has been the subject of several recent analyst reports. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, B. Riley Financial began coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price for the company.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently modified their holdings of AAPG. UBS Group AG grew its position in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000. Finally, Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the third quarter worth $383,000.

Ascentage Pharma Group International Stock Up 3.6%

Shares of NASDAQ:AAPG opened at $16.81 on Thursday. Ascentage Pharma Group International has a 1 year low of $16.23 and a 1 year high of $41.72. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The business’s 50-day moving average is $18.21 and its 200-day moving average is $20.80.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. On average, research analysts anticipate that Ascentage Pharma Group International will post -2.42 EPS for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.